​

Ocular Therapeutix (OCUL) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

OCUL Stock Forecast

Ocular Therapeutix (OCUL) stock forecast, based on 17 Wall Street analysts, predicts a 12-month average price target of $25.75, with a high of $31.00 and a low of $19.00. This represents a 122.94% increase from the last price of $11.55.

- $7 $14 $21 $28 $35 High: $31 Avg: $25.75 Low: $19 Last Closed Price: $11.55

OCUL Stock Rating

Ocular Therapeutix stock's rating consensus is Buy, based on 17 Wall Street analysts. The breakdown includes 1 Strong Buy (5.88%), 14 Buy (82.35%), 2 Hold (11.76%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 17 0 2 14 1 Strong Sell Sell Hold Buy Strong Buy

OCUL Price Target Upside V Benchmarks

TypeNameUpside
StockOcular Therapeutix122.94%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts445
Avg Price Target$25.75$25.75$24.40
Last Closing Price$11.55$11.55$11.55
Upside/Downside122.94%122.94%111.26%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 2557---12
Sep, 2556---11
Aug, 2566---12
Jul, 2566---12
Jun, 2566---12
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 08, 2025H.C. Wainwright$19.00$11.5264.93%64.50%
Oct 03, 2025Piper Sandler$31.00$11.06180.29%168.40%
Oct 03, 2025Colleen KusyRobert W. Baird$24.00$11.06117.00%107.79%
Oct 01, 2025Jonathan WollebenJMP Securities$29.00$11.69148.08%151.08%
Mar 04, 2025JMP Securities$19.00$6.50192.31%64.50%
Aug 08, 2024Colleen KusyRobert W. Baird$17.00$8.37103.11%47.19%
Jun 27, 2024Biren AminPiper Sandler$15.00$6.71123.55%29.87%
Jun 14, 2024Yi ChenH.C. Wainwright$14.00$5.89137.69%21.21%
Mar 12, 2024Jonathan WollebenJMP Securities$24.00$9.29158.34%107.79%
Jun 07, 2022Joseph CatanzaroPiper Sandler$10.00$3.78164.55%-13.42%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 08, 2025H.C. WainwrightBuyBuyhold
Oct 03, 2025Piper SandlerOverweightOverweighthold
Oct 01, 2025CitigroupOutperformOutperformhold
Oct 16, 2024H.C. WainwrightBuyBuyhold
Sep 19, 2024Piper SandlerOverweightOverweighthold
Aug 01, 2024Sandler O'NeillMarket OutperformMarket Outperformhold
Jun 27, 2024Piper SandlerOverweightOverweighthold
Jun 20, 2024Cowen & Co.HoldBuyupgrade
Jun 14, 2024H.C. WainwrightUnderperformUnderperformhold
Jun 14, 2024H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.63$-0.14$-0.83$-1.09$-1.22----
Avg Forecast$-1.18$-1.03$-0.95$-0.99$-1.18$-1.07$-1.06$-0.93$0.09
High Forecast$-1.08$-0.94$-0.87$-0.91$-1.16$-0.95$-0.98$-0.33$0.11
Low Forecast$-1.35$-1.18$-1.07$-1.04$-1.20$-1.28$-1.18$-1.59$0.08
Surprise %122.88%-86.41%-12.63%10.10%3.39%----

Revenue Forecast

$0 $100M $200M $300M $400M $500M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$17.40M$43.52M$51.49M$58.44M$63.46M----
Avg Forecast$22.33M$45.03M$50.82M$59.39M$63.74M$72.25M$84.03M$145.11M$418.65M
High Forecast$24.84M$50.09M$55.96M$59.79M$64.71M$77.51M$95.08M$150.91M$473.71M
Low Forecast$20.84M$42.01M$47.44M$58.78M$62.41M$67.20M$76.86M$139.30M$382.93M
Surprise %-22.08%-3.35%1.33%-1.59%-0.43%----

Net Income Forecast

$-200M $-150M $-100M $-50M $0 $50M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-159.63M$-10.80M$-63.42M$-80.74M$-193.51M----
Avg Forecast$-101.13M$-1.33M$-35.73M$-80.74M$-101.02M$-95.59M$-92.61M$-82.14M$7.96M
High Forecast$-92.30M$3.42M$-26.36M$-59.90M$-99.33M$-81.69M$-83.84M$-27.91M$9.32M
Low Forecast$-115.90M$-6.08M$-45.10M$-101.58M$-102.72M$-109.50M$-101.38M$-136.37M$7.07M
Surprise %57.85%714.69%77.50%-91.54%----

OCUL Forecast FAQ

Is Ocular Therapeutix stock a buy?

Ocular Therapeutix stock has a consensus rating of Buy, based on 17 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 14 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Ocular Therapeutix is a favorable investment for most analysts.

What is Ocular Therapeutix's price target?

Ocular Therapeutix's price target, set by 17 Wall Street analysts, averages $25.75 over the next 12 months. The price target range spans from $19 at the low end to $31 at the high end, suggesting a potential 122.94% change from the previous closing price of $11.55.

How does Ocular Therapeutix stock forecast compare to its benchmarks?

Ocular Therapeutix's stock forecast shows a 122.94% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Ocular Therapeutix over the past three months?

  • October 2025: 41.67% Strong Buy, 58.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 45.45% Strong Buy, 54.55% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Ocular Therapeutix’s EPS forecast?

Ocular Therapeutix's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.07, marking a -12.30% decrease from the reported $-1.22 in 2024. Estimates for the following years are $-1.06 in 2026, $-0.93 in 2027, and $0.09 in 2028.

What is Ocular Therapeutix’s revenue forecast?

Ocular Therapeutix's average annual revenue forecast for its fiscal year ending in December 2025 is $72.25M, reflecting a 13.85% increase from the reported $63.46M in 2024. The forecast for 2026 is $84.03M, followed by $145.11M for 2027, and $418.65M for 2028.

What is Ocular Therapeutix’s net income forecast?

Ocular Therapeutix's net income forecast for the fiscal year ending in December 2025 stands at $-95.595M, representing a -50.60% decrease from the reported $-194M in 2024. Projections indicate $-92.61M in 2026, $-82.14M in 2027, and $7.96M in 2028.